knowledge -WSS

knowledge

author：entertainment 2025-08-11 16:25:08 - browse：67265

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Pregnant women don't need prenatal multivitamins, study concludes

Wikipedia

WSS

Statins may not be needed by millions of people, study suggests

Medicare drug price negotiation hearing pits pharma v Biden admin

State of the Union pitch: Bigger Medicare drug price negotiations

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Moderna says combo Covid

Why Talkspace is targeting Medicare, a tricky market

knowledge

knowledge

focus

Hollywood unions extend contract negotiations for actors

Biden's 'march

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

My daughter's legacy lives on through her writing, phage therapy

Moonlake's readout produced a cash windfall. Risks remain

ALS patient reclaims some autonomy thanks to wearable 'robot'

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Families look for replacement for GSK asthma drug Flovent

As demand for Covid shots wanes, Moderna seeks its next success

'Essentially witchcraft:' A former naturopath takes on the field

entertainment

Coercive sterilizations revealed by STAT prompt outrage

Ozempic has benefits for kidney disease as well as diabetes

How faith leaders like me can help address America's obesity epidemic

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

The system is set up to fail children with medical complexity

Immune cells and nerve overgrowth may explain recurring UTI pain

Wikipedia

hotspot

entertainment

entertainment